Cord Blood America reviews first quarter results

Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that its co-founder and CEO, Matthew Schissler, reviewed first quarter results and progress in an interview with analyst Francis Gaskins.

The entire interview is available at:

http://gaskinsco.com/cbai-5-20-10.mp3

In the interview, Mr. Schissler says:

• The acquisition announced in Germany is an anchor for business expansion throughout Europe through the use of affiliates.
• The Company is on-track, with its partner AXM Pharma, to open the world's largest stem cell storage and processing facility in China by January 2011.  The model is to develop a "cellular pharmacy" at which stem cells will be used in the future to create pharmaceuticals.
• Due diligence continues on the purchase of a large stem cell company headquartered in Argentina with affiliates throughout South America.  
• All the Company's umbilical cord blood stem cells have been transferred and are now housed at its Las Vegas facility.
• There was essentially no dilution of common stock in the first quarter.  "The stock price does not reflect our achievements but we believe if we continue to execute, it will bring buyers back to CBAI," Mr. Schissler said.

Source: Cord Blood America